cis-3-caffeoylquinic acid | 327-97-9

• 物质功能分类: 天然产物 - 酚类
• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: cis-3-caffeoylquinic acid
• 英文别名: (1S)-3c-[3c-(3,4-dihydroxy-phenyl)-acryloyloxy]-1,4t,5t-trihydroxy-cyclohexane-r-carboxylic acid；cis-Neochlorogenin-saeure；cis-Chlorogenin-saeure；(Z)-chlorogenic acid；3-{[(2Z)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-1,4,5-trihydroxycyclohexane-1-carboxylic acid；3-[(Z)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid
• CAS: 327-97-9；534-61-2；906-33-2；15016-60-1；15076-00-3；29587-84-6；32719-11-2；72690-58-5；77209-78-0；82659-69-6；82659-70-9；82659-71-0；82690-55-9；93451-45-7；93451-46-8
• 化学式: C₁₆H₁₈O₉
• 分子量: 354.314
• InChiKey: CWVRJTMFETXNAD-RQOWECAXSA-N

物化性质

• 熔点：
  210 °C (dec.) (lit.)
• 比旋光度：
  -36 º (c=1, H2O)
• 沸点：
  407.55°C (rough estimate)
• 密度：
  1.3594 (rough estimate)
• 溶解度：
  易溶于乙醇和丙酮。
• LogP：
  -0.356 (est)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  165
• 氢给体数：
  6
• 氢受体数：
  9

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R68
• WGK Germany：
  3
• 海关编码：
  29182900
• RTECS号：
  GU8480000
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

制备方法与用途

绿原酸是一种天然化合物，广泛存在于忍冬科、千屈菜科等植物中。它具有多种生物活性和潜在的药用价值。

化学性质：

• 熔点：208℃（无水物）
• 溶解性：易溶于乙醇及丙酮，极微溶于醋酸乙酯
• 旋光度：[α]20D -35.2

用途和药理作用：

1. 抗菌作用：绿原酸具有广谱抗菌活性，能有效抑制多种细菌的生长。
2. 解热镇痛：用于治疗上呼吸道感染、消炎解热等。
3. 免疫调节：有助于提高白细胞数量，增强机体免疫力。
4. 抗病毒：能够抑制病毒感染和复制。
5. 抗氧化作用：具有清除自由基的能力，保护细胞免受氧化损伤。

化学合成方法：

绿原酸可以通过化学合成获得。例如从緑咖啡豆中分离得到的步骤如下：

1. 提取：通过溶剂萃取或酶解等方式从植物材料中提取含绿原酸的组分。
2. 纯化：使用柱层析、结晶等方法进一步提纯绿原酸。
3. 精制与干燥：对粗产品进行必要的洗涤、过滤及干燥处理，最终获得纯度较高的绿原酸。

安全性：

• 绿原酸对人有轻微致敏作用，但口服一般不会引起过敏反应。其毒性较小，经动物实验测定的大鼠腹腔注射半数致死量（LD50）大于0.25g/kg。
• 需要避免在火场使用时产生辛辣刺激性烟雾，并采取适当的安全防护措施。

生产与储存：

• 通常需要储存在低温、通风良好的干燥环境中以保持其稳定性和活性。
• 运输过程中应同样注意防潮和温度控制，防止因环境因素导致的降解。

综上所述，绿原酸是一种重要的天然产物，在医药保健领域有着广泛的应用前景。

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF RENAL DISEASES<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE NÉPHROPATHIES
  申请人：MOHAN M ALAPATI

  公开号：WO2016046670A1

  公开（公告）日：2016-03-31

  The compositions and compounds of formula I which includes a salt of pyridoxamine or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, nanoparticle, buccal administration or transdermal administration. Such compositions may be used to treatment of kidney disease, diabetic renal diseases, chronic kidney disease, albuminuria, or its associated complications.

  公式I的组合物和化合物包括吡啶醇盐或其多晶形、对映体、立体异构体、溶剂合物和水合物。这些盐可以制成药物组合物。药物组合物可以制成口服、延迟释放或持续释放、经粘膜、糖浆、局部、肠道、注射、皮下、口服溶液、直肠给药、纳米颗粒、颊黏膜给药或经皮给药的制剂。这些组合物可用于治疗肾脏疾病、糖尿病肾病、慢性肾脏疾病、白蛋白尿或其相关并发症。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
  申请人：Alapati Mohan Murali

  公开号：US20170129870A1

  公开（公告）日：2017-05-11

  The compositions and compounds of Formula I which includes a salt of duloxetine or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of major depressive disorder, general anxiety disorder, urinary incontinence, painful peripheral neuropathy, diabetic neuropathy, fibromyalgia, and chronic musculoskeletal pain associated with osteoarthritis and chronic lower back pain.

  Formula I的组成和化合物包括度洛西汀盐或其多晶形、对映体、立体异构体、溶剂合物和水合物。这些盐可以制成药物组合物。药物组合物可以制成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射用药物组合物。这些组合物可用于治疗重性抑郁障碍、广泛性焦虑障碍、尿失禁、疼痛性周围神经病、糖尿病性神经病、纤维肌痛和与骨关节炎和慢性腰背痛相关的慢性肌肉骨骼疼痛。
• GREASE COMPOSITION, GREASE-PACKED BEARING, UNIVERSAL JOINT FOR PROPELLER SHAFT, LUBRICATING OIL COMPOSITION, AND OIL-IMPREGNATED SINTERED BEARING
  申请人：Mikami Hidenobu

  公开号：US20110306429A1

  公开（公告）日：2011-12-15

  The present invention provides a grease composition or a lubricating oil composition which is capable of effectively preventing hydrogen brittleness-caused peeling from occurring on a rolling surface of a rolling bearing, is excellent in durability in a high temperature and speed operation, and can be used for a long time. A grease-packed bearing ( 1 ) has an inner ring ( 2 ), an outer ring ( 3 ), and a plurality of rolling elements ( 4 ). A sealing member ( 6 ) for sealing a grease composition ( 7 ) is provided at openings ( 8 a ) and ( 8 b ) disposed at both axial ends of the inner ring ( 2 ) and the outer ring ( 3 ). The grease composition ( 7 ) includes a base grease composed of a base oil and a thickener and an additive added to the base grease. The additive contains at least one compound selected from among plant-derived polyphenolic compounds and compounds formed by decomposition thereof. The above-described compounds include tannin, gallic acid, ellagic acid, chlorogenic acid, caffeic acid, curcumin, quercetin, and quinic acid.
• Rolling bearing
  申请人：Mikami Hidenobu

  公开号：US20110311173A1

  公开（公告）日：2011-12-22

  The present invention provides a rolling bearing which is excellent in high-temperatures and high-speed durability and quietness, is capable of effectively preventing hydrogen brittleness-caused peeling from occurring on a rolling surface thereof, and has a low environmental load. A rolling bearing ( 1 ) is constructed of an inner ring ( 2 ) having a rolling surface on its peripheral surface, an outer ring ( 3 ) having a rolling surface on its inner peripheral surface, a plurality of rolling elements ( 4 ) disposed between both rolling surfaces, and a cage ( 5 ) retaining the rolling elements ( 4 ). The inner ring ( 2 ), the outer ring ( 3 ), the rolling elements ( 4 ) or the cage ( 5 ) is a metal-made bearing member. Film-coating treatment is conducted on a sliding surface or a rolling surface of at least one of these metal-made bearing members with the plant-derived polyvalent alcohol compounds such as curcumin, quercetin, chlorogenic acid or the like.
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES
  申请人：Alapati Mohan Murali

  公开号：US20170073345A1

  公开（公告）日：2017-03-16

  The invention relates to the compounds and compositions of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of dipeptidyl peptidase-4 inhibitor and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compounds and compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.